Joint venture · GCC · Announced 8 Nov 2026

Alkem Laboratories → Vitals Biotech

India's Alkem Laboratories incorporated Alkem Pharma Company, a Saudi joint venture it owns 51%, with SAR 7.5 million (about US$2 million) capital, to make, import, market and distribute pharmaceutical and nutraceutical products in Saudi Arabia.

Parties: Alkem Laboratories (India) → Vitals Biotech Company (Saudi Arabia)

Deal type
Joint venture
Value
$2m
Territory
Saudi Arabia
Therapeutic area
Multi-therapy
Asset
Alkem Pharma Company
Announced
8 Nov 2026

Our analysis

Why this matters

Alkem Laboratories, one of India's largest drugmakers, told Indian stock exchanges on 8 November 2026 that it has incorporated Alkem Pharma Company, a limited liability joint venture in Saudi Arabia. Alkem holds 51% and subscribed 38,250 shares of SAR 100 each, SAR 3.825 million in cash. The company's total share capital is SAR 7.5 million (75,000 shares), about US$2 million.

The JV's stated business is the manufacture, import, marketing and distribution of pharmaceutical and/or nutraceutical products. No products, brands, therapeutic areas, site or launch dates were disclosed. Alkem says the move is to expand its business and market reach in the Kingdom.

The full analysis is free to read with a work email on this page.

Source: TipRanks (Alkem stock-exchange disclosure)

Latest deals

All GCC deals → · All joint venture deals → · Browse all emerging-market pharma deals →